Literature DB >> 21857688

Stromal targeted therapy in bone metastatic prostate cancer: promise delivered.

Oliver Sartor1, William Goeckeler, Oyvind Bruland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21857688      PMCID： PMC3739571          DOI： 10.1038/aja.2011.120

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  15 in total

Review 1.  Treatment of Hodgkin's disease.

Authors:  V T De Vita; S M Hubbard; D L Longo
Journal:  J Natl Cancer Inst Monogr       Date:  1990

Review 2.  High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

Authors:  Øyvind S Bruland; Sten Nilsson; Darrell R Fisher; Roy H Larsen
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

3.  High-LET radiations induce a large proportion of non-rejoining DNA breaks.

Authors:  M A Ritter; J E Cleaver; C A Tobias
Journal:  Nature       Date:  1977-04-14       Impact factor: 49.962

4.  Samarium-153-EDTMP biodistribution and dosimetry estimation.

Authors:  J F Eary; C Collins; M Stabin; C Vernon; S Petersdorf; M Baker; S Hartnett; S Ferency; S J Addison; F Appelbaum
Journal:  J Nucl Med       Date:  1993-07       Impact factor: 10.057

5.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 7.  Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications.

Authors:  Leland W K Chung
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

8.  The short-term fixation of radiopharmaceuticals in bone.

Authors:  C Schümichen; H Rempfle; M Wagner; G Hoffmann
Journal:  Eur J Nucl Med       Date:  1979-12

9.  Skeletal localization of samarium-153 chelates: potential therapeutic bone agents.

Authors:  W F Goeckeler; B Edwards; W A Volkert; R A Holmes; J Simon; D Wilson
Journal:  J Nucl Med       Date:  1987-04       Impact factor: 10.057

10.  Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

Authors:  Sten Nilsson; Lars Franzén; Christopher Parker; Christopher Tyrrell; René Blom; Jan Tennvall; Bo Lennernäs; Ulf Petersson; Dag C Johannessen; Michael Sokal; Katharine Pigott; Jeffrey Yachnin; Michael Garkavij; Peter Strang; Johan Harmenberg; Bjørg Bolstad; Oyvind S Bruland
Journal:  Lancet Oncol       Date:  2007-07       Impact factor: 41.316
View more
  2 in total

1.  Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort.

Authors:  Sonam Suman; Rahul V Parghane; Amit Joshi; Kumar Prabhash; Ganesh Bakshi; Sanjay Talole; Sharmila Banerjee; Sandip Basu
Journal:  Br J Radiol       Date:  2019-11-01       Impact factor: 3.039

2.  Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.

Authors:  A Som; S-M Tu; J Liu; X Wang; W Qiao; C Logothetis; P G Corn
Journal:  Br J Cancer       Date:  2012-10-02       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.